Bioxel files patents for semi-synthesis manufacturing of paclitaxel and docetaxel

By Angela McDaniels

Seattle, Nov. 18 - Bioxel Pharma Inc. said it has filed a new patent covering the manufacturing of paclitaxel and docetaxel active pharmaceutical ingredients by semi-synthesis.

"This new intellectual property serves clear commercial objectives," said Pascal Delmas, Bioxel president and chief executive officer, in a company news release.

"First, it will broaden our product line. Second, it will satisfy the demand of our pharmaceutical partners that are seeking semi-synthetic taxanes manufactured using highly efficient processes with guaranteed freedom to operate.

"These patents not only strengthen Bioxel's market position for paclitaxel, they also allow us to develop our new docetaxel product, for which there is a significant market opportunity."

The patent strengthens and extends the patent previously filed by the company in March 2005 on synthetic taxane intermediates, the company said.

Docetaxel is the active pharmaceutical ingredient manufactured by Sanofi-Aventis. Marketed under the trade name Taxotere, it generates annual worldwide revenues of about $2 billion.

Generic drug product manufacturers are positioning themselves to take advantage of patent expiration on docetaxel in 2007, the company said.

Bioxel said it is discussing the supply of semi-synthetic taxanes with pharmaceutical customers for deliveries starting in 2006.

Based in Sainte-Foy, Quebec, Bioxel is a biopharmaceutical company that develops taxane pharmaceutical ingredients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.